Page 110 - The Flying Publisher Guide to Hepatitis C Treatment
P. 110
110 | Hepatitis C Treatment
HCV antibodies 30 NS5A inhibitors 72
HCV genotype 17, 31, 47, 51, Nucleic acid testing 31
59, 66, 74, 86, 102 Null responders 27, 44, 66
HCV genotyping 34
HCV RNA 14, 17, 24, 25, 46 Obesity 19, 56
HCV RNA genotyping 31 Omega interferon 60, 63
Hemodialysis 53
HepaScore 39 Partial responders 51, 66
Hepatocellular carcinoma 13 Pegasys 15, 101
HIV-HCV coinfection 41, 55 PegIFN alfa-2a 15, 16
PegIFN alfa-2b 15, 16
IDX 184 75 PegIFN lambda 60
IFN lambda 61 Peg-Intron 102
IFN XL 63 Pegylated interferon 13, 102
IL28B gene 18 pEVR 25
Immunosuppression 73, 81 Polymerase inhibitors 70, 72
Incivek 14, 66, 105 Preemptive antiviral therapy
Infergen 60, 103 84
Injecting drug users 52 Procleix 31
Insulin resistance 20, 56 Protease inhibitor 14, 17, 20,
Interferon alfacon 60 26, 48, 51, 65, 105, 107
Interferons 14 PSI-7977 75
new formulations 59
ITX 5061 75 Quasispecies 17
LCx HCV RNA Quantitative 33 R7128 71, 72
Liver biopsy 35 R7227 70, 72
Liver transplantation 13, 74, Race 18, 19
79 Rapid virological response 25
Locteron 60, 63 Real-time PCR 31, 32
Rebetol 103, 104
Medusa delivery system 63 Relapsers 27, 43, 44, 45, 50, 59,
Mericitabine 71, 75 66
Metabolic syndrome 56 Resistance 34, 66, 71, 73
MK-5172 70 Response-guided therapy 24
Mycophenolate mofetil 82 Retransplantation 80, 88
Retreatment 43, 44, 45, 46, 47,
Neutropenia 22 51, 61
Non-responders 43, 44, 45, 46, RGT 24
50 Ribavirin 16
